Ontario Teachers Pension Plan Board Takes Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Key Points

• The Ontario Teachers Pension Plan Board has acquired a new stake in Lantheus Holdings, purchasing 17,759 shares valued at approximately $1.73 million.
• During the first quarter, several institutional investors increased their holdings in Lantheus, collectively owning 99.06% of the company’s stock.
• Lantheus reported a quarterly earnings miss with earnings per share of $1.57, falling short of analysts' estimates by $0.08, and experienced a 4.1% decline in revenue year-over-year.

Ontario Teachers Pension Plan Board bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 17,759 shares of the medical equipment provider's stock, valued at approximately $1,733,000.

A number of other hedge funds have also recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. increased its stake in Lantheus by 3.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,084 shares of the medical equipment provider's stock worth $1,162,000 after purchasing an additional 400 shares during the period. State of Alaska Department of Revenue increased its stake in Lantheus by 2.7% in the first quarter. State of Alaska Department of Revenue now owns 8,142 shares of the medical equipment provider's stock worth $794,000 after purchasing an additional 215 shares during the period. GAMMA Investing LLC increased its stake in Lantheus by 12,517.1% in the first quarter. GAMMA Investing LLC now owns 128,442 shares of the medical equipment provider's stock worth $12,536,000 after purchasing an additional 127,424 shares during the period. Cerity Partners LLC increased its stake in Lantheus by 12.7% in the first quarter. Cerity Partners LLC now owns 11,709 shares of the medical equipment provider's stock worth $1,143,000 after purchasing an additional 1,323 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in Lantheus by 1,196.4% in the first quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider's stock worth $32,817,000 after purchasing an additional 310,301 shares during the period. Institutional investors own 99.06% of the company's stock.

Lantheus Stock Up 5.8%

Lantheus stock opened at $54.86 on Friday. The business has a fifty day moving average of $76.68 and a two-hundred day moving average of $87.17. The company has a quick ratio of 5.46, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The firm has a market cap of $3.80 billion, a P/E ratio of 14.59 and a beta of 0.14. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). The company had revenue of $378.05 million for the quarter, compared to analysts' expectations of $389.69 million. Lantheus had a return on equity of 34.06% and a net margin of 17.82%. The firm's quarterly revenue was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.80 EPS. On average, analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on LNTH. William Blair reiterated a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. Truist Financial dropped their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. B. Riley dropped their price objective on Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research note on Monday, June 23rd. Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, JMP Securities dropped their price objective on Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a research note on Thursday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Lantheus currently has an average rating of "Moderate Buy" and an average price target of $114.50.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the sale, the director owned 318,650 shares in the company, valued at $24,481,879.50. This represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.